By Mariam Sunny and Michael Erman Feb 13 (Reuters) - Moderna said it is looking for growth overseas after the U.S. FDA ...

Here are some of the biggest movers in midday trading. Moderna – Shares of the biotech giant climbed 5% after the company ...

Moderna will report its fourth-quarter 2025 earnings this morning in an investor call that’s taken on even more interest in ...

Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% ...

Moderna said its new flu shot has been cleared for review in Australia, Canada and the European Union. It has asked to meet ...

Moderna received a refusal-to-file letter from the FDA objecting to how it conducted a 40,000-person trial comparing its new ...

The head of the agency’s vaccine division, Vinay Prasad, has overruled pushback from career staffers.

The federal government on Wednesday told its side of the story amid a disagreement with Moderna after the FDA decided to ...

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well ...

In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...